In addition, sPD-L1 levels in cHL patients decreased to healthy control levels after achieving complete remission through chemotherapy, indicating that dynamic monitoring of sPD-L1 can be used for efficacy evaluation. The gene discussed is SPDL1; the disease is classic Hodgkin lymphoma.